Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

NCT03462212 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

290

Enrollment

OTHER

Sponsor class

Conditions

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Interventions

DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Bevacizumab
DRUG: Rucaparib

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborators

[object Object]
[object Object]